Sanofi registers Phase 2b hidradenitis suppurativa trial; RSV+HMPV vaccine study recruiting

Sanofi posted two Phase 2b registry updates this week covering a new dermatology trial and continued enrollment in a respiratory vaccine study.

• Duvakitug (SAR447189), a Phase 2b subcutaneous injection for moderate to severe hidradenitis suppurativa, was newly registered and is not yet recruiting. The trial, called "AURALIGHT," will enroll 156 participants across arms testing two dose regimens against placebo¹, with the primary endpoint being the percentage of participants achieving Hidradenitis Suppurativa Clinical Response 75 (HiSCR75) at Week 16¹.
• The bivalent RSV+HMPV protein vaccine candidate (RPF08203), a Phase 2b intramuscular injection study in adults 60 and older, is recruiting. The trial plans to enroll approximately 8000 participants to assess clinical efficacy, safety, and immunogenicity of a single dose², starting with a 200-participant Safety Lead-in Cohort randomized 1:1 to vaccine or placebo² before the larger main cohort begins.